Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
The purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients (n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (six×28-day cycles) treatment. In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2–L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years. At the end of the 2-year goserelin-treatment period, mean BMD losses for goserelin-treated and CMF-treated patients were −10.5% and −6.5% (P=0.0005) for lumbar spine and −6.4% and −4.5% (P=0.04) for femoral neck, respectively. At 3 years, partial recovery of BMD was observed in goserelin recipients. In contrast, mean BMD losses for the CMF group indicated persistent BMD loss. No significant differences in BMD were observed between groups at the 3-year assessment of the spine or femoral neck. In the CMF group, based on amenorrhea status at 48 weeks, BMD losses at the lumbar spine were greater for amenorrheic than non-amenorrheic patients. Ovarian suppression resulting in amenorrhea was closely related to BMD loss in both treatment groups. Overall, patients who received CMF did not show recovery of BMD throughout follow-up, whereas partial recovery was observed 1 year after cessation of goserelin therapy, associated with the return of ovarian function in the majority of patients.
KeywordsBone mineral density Goserelin Node-positive early breast cancer Premenopausal ZEBRA
The ZEBRA study is supported by a grant from AstraZeneca, Macclesfield, UK. Participating investigators: M. Geberth, Heidelberg, Germany; B. Lisboa, Hamburg, Germany; A.X. Izquierdo, Gerona, Spain; P. Firat, Ankara, Turkey; S.J. Leinster, Liverpool, UK.
- 2.Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsh A, Rudenstam CM et al. (1998) Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640CrossRefPubMedGoogle Scholar
- 3.Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M et al. (2002) Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study. J Clin Oncol 20:4628–4635CrossRefPubMedGoogle Scholar
- 4.Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P et al. (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718–2727PubMedGoogle Scholar
- 5.Jakesz R, Hausmaninger H, Samonigg H et al. (2001) Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and -negative patients with hormone-responsive breast cancer. Breast 10:S10 (abstract S26)Google Scholar
- 6.Davidson N, O’Neill A, Vukov A, Osborne S, Martino D, White M.D (1999) Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup trial. Proc ASCO 18:67a (abstract 249)Google Scholar
- 7.Baum M, Houghton J, Odling-Smee W et al. (2001) Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP trial. Breast 10:S32–S33 (abstract P64)Google Scholar
- 8.de Haes H and the ZEBRA Trialists Group (2000) Comparison of quality of life in pre/perimenopausal women treated with Zoladex or CMF as adjuvant therapy for the management of node-positive early breast cancer: results from the ZEBRA study. Breast Pharmacokinet 39:27–48Google Scholar
- 10.Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T et al. (2002) Randomized adjuvant trial of tamoxifen plus goserelin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. J Clin Oncol 20:4621–4627CrossRefPubMedGoogle Scholar
- 11.Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Aldrighetti D et al. (2001) CMF vs tamoxifen (TAM) plus ovarian suppression (OS) as adjuvant treatment of ER-positive (ER+) pre/perimenopausal breast cancer (BCA) patients. Breast 10:S32 (abstract P62)Google Scholar
- 12.Trevisan C, Ortolani S, Bianchi ML, Caraceni MP, Ulivieri FM, Gandolini G, Polli EE (1991) Age, time since menopause, and body parameters as determinants of female spinal bone mass: a mathematical model. Calcif Tiss Int 49:1–5Google Scholar
- 16.Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341–1347PubMedGoogle Scholar
- 29.Namer M, Jonat W, Kaufmann M, Blamey R, Cuzick J, Fogelman I et al. (2002) Survival data from the ZEBRA study. Ann Oncol 13 (suppl 5):38 (abstract 135P)Google Scholar